- Home
- MESO vs UWMC Comparison
MESO vs UWMC Comparison
Compare MESO & UWMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- UWMC
- Stock Information
- Founded
- MESO 2004
- UWMC 1986
- Country
- MESO Australia
- UWMC United States
- Employees
- MESO 81
- UWMC N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- UWMC Finance: Consumer Services
- Sector
- MESO Health Care
- UWMC Finance
- Exchange
- MESO Nasdaq
- UWMC Nasdaq
- Market Cap
- MESO 2.0B
- UWMC 1.4B
- IPO Year
- MESO N/A
- UWMC N/A
- Fundamental
- Price
- MESO $15.60
- UWMC $5.77
- Analyst Decision
- MESO Buy
- UWMC Hold
- Analyst Count
- MESO 2
- UWMC 8
- Target Price
- MESO $24.00
- UWMC $6.46
- AVG Volume (30 Days)
- MESO 213.4K
- UWMC 8.9M
- Earning Date
- MESO 08-28-2025
- UWMC 11-06-2025
- Dividend Yield
- MESO N/A
- UWMC 6.92%
- EPS Growth
- MESO N/A
- UWMC 112.84
- EPS
- MESO N/A
- UWMC 0.07
- Revenue
- MESO $17,198,000.00
- UWMC $2,622,828,000.00
- Revenue This Year
- MESO $288.50
- UWMC $11.44
- Revenue Next Year
- MESO $167.17
- UWMC $12.48
- P/E Ratio
- MESO N/A
- UWMC $87.20
- Revenue Growth
- MESO 191.39
- UWMC 13.45
- 52 Week Low
- MESO $8.34
- UWMC $3.80
- 52 Week High
- MESO $22.00
- UWMC $7.14
- Technical
- Relative Strength Index (RSI)
- MESO 39.64
- UWMC 51.48
- Support Level
- MESO $16.10
- UWMC $5.45
- Resistance Level
- MESO $16.91
- UWMC $5.90
- Average True Range (ATR)
- MESO 0.50
- UWMC 0.20
- MACD
- MESO -0.27
- UWMC 0.03
- Stochastic Oscillator
- MESO 0.60
- UWMC 75.66
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.